Svetlana O. Doronina

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

Pharmacy, Medicinal Chemistry, Oncology +14

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 921 citations

Medicine, Medicinal Chemistry, Oncology +11

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Robert P. Lyon, Tim D. Bovee, Svetlana O. Doronina et al. · Nature Biotechnology · 2015 · 523 citations

Pharmacy, Pharmaceutics, Pharmacokinetics +14

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity

Svetlana O. Doronina, Brian A. Mendelsohn, Tim D. Bovee et al. · Bioconjugate Chemistry · 2005 · 512 citations

Pharmacy, Oncology, Pharmacology +17

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

Robert P. Lyon, Jocelyn R. Setter, Tim D. Bovee et al. · Nature Biotechnology · 2014 · 445 citations

Pharmacy, Pharmaceutics, Pharmacology +16